Correction: Biocept Q1 Revenues Fall 20 Percent | GenomeWeb

The headline has been corrected to state that Biocept's first quarter revenues decreased, not increased, 20 percent.

NEW YORK (GenomeWeb) – Newly publicly traded firm Biocept yesterday reported a 20 percent drop year over year in its first quarter revenues.

In a Form 10-Q filed with the US Securities and Exchange Commission, the San Diego-based firm said that revenues shrank to $28,275 for the three months ended March 31, compared to $35,154 in the year-ago quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.